Abstract
Introduction

Tumourigenesis has traditionally been described as a cellautonomous process when a cell, after accumulation of genetic alterations, loses its control over growth, undergoes aberrant proliferation and thus gives rise to a tumour. It is now accepted that the microenvironment surrounding a potential tumour cell plays a crucial role influencing its fate [1]. For instance, experiments exposing pre-neoplastic or tumour cells to various mesenchymal environments have underlined the critical role of the stroma in this context
. Among the proteins known to be overexpressed in tumour-associated stroma are tenascin-C and tenascin-W.
Tenascins are large glycoproteins found in the extracellular compartment of various tissues. The tenascin family has four members: tenascin-C, tenascin-R, tenascin-X and tenascin-W. They all share a characteristic modular structure with an oligomerization domain followed by EGF-like repeats, fibronectin (FN) type III repeats and a fibrinogen globe (see Ref. [5] and Fig. 1). In the case of tenascin-C and tenascin-R, alternative splicing can lead to the generation of multiple isoforms that contain additional FN type III repeats. Only two of the tenascin members, the original tenascin-C [6, 7] and the more recently discovered tenascin-W [8], have been shown to be overexpressed in tumours compared to healthy tissues (for review, see Ref. [9]). In most cases, healthy tissues are not completely deprived of tenascin-C [10].
However, corresponding tumour tissues express much higher levels of tenascin-C or harbour different, larger isoforms [11] . Tenascin-W expression is much more restricted in adult healthy tissues [10] , which makes it an excellent tumour marker: it is absent in healthy tissue but present in most breast [12] 
Birth of a malignant cell
Expression patterns in tumours
In tumours arising from epithelial organs (i.e. in most carcinomas), the source of tenascins is restricted to the structural, mesenchymal compartment: very strong tenascin immunostaining is found in the tumour stroma surrounding tenascin-free tumour nests (see Fig. 1 
, for a typical staining pattern). The stromal tenascin-C expression can be influenced by cancer cells because co-culture of fibroblasts with tumour cells has been shown to stimulate tenascin-C expression in the fibroblasts [29, 30]. In other tumours such as melanoma and brain tumours, the tumour cells themselves are the source of tenascin-C [31, 32]. Interestingly, brain tumours arise from structural cells (oligodendrocytes for oligodendrogliomas, astrocytes for astrocytomas and glioblastomas), which may explain that these cells have common features with mesenchymal cells rather than with carcinoma cells. Melanomas develop from neural crest-derived melanocytes. Neural crest cells express high levels of tenascin-C [33], which is required for their migration in embryogenesis [34]. In contrast to tenascin-C, tenascin-W expression has yet to be described in tumour cells themselves. However, tenascin-W is also expressed in the stroma of breast and colon carcinomas. In brain tumours, both tenascin-C and tenascin-W can be observed around blood vessels. However, their pattern of expression is distinct because tenascin-C surrounds both endothelial and pericyte cell layers, whereas tenascin-W is restricted to the endothelial cell layer [14].
Promotion of tumour cell proliferation
An important feature of tumour cells is their ability to overproliferate. Interestingly, tenascin-C has been shown to promote tumour cell proliferation in standard cell culture conditions [7, 35] 14-3-3 [75] followed by p21 down-regulation [76] .
Promotion of tumour cell migration
Contribution to epithelial-mesenchymal transition (EMT)
Epithelial
recent study reports that tenascin-C is required for injury-induced EMT of lens epithelium [51]. However, except for the last example, it remains to be determined whether tenascin-C expression is only a consequence of EMT or may also be required for this process.
Promotion of angiogenesis
When a tumour reaches a critical size, it has to attract the formation of new vessels to supply nutrients and oxygen to the proliferating cells. Both tenascin-C and tenascin-W can been classified as pro-angiogenic factors because they trigger endothelial cells to acquire a sprouting phenotype and increase their migration capacities [14, 52, 53]. Tenascin-C is known to play a crucial role in postnatal cardiac angiogenesis because tenascin-C-deficient mice fail to vascularize cardiac allografts in an established cardiac transplantation model [54]. Furthermore, in a xenograft tumour model it was shown that tumours were much more vascularized when they were grown in wild-type mice than in tenascin-C-deficient mice, suggesting that the presence of tenascin-C in the microenvironment is very important for tumour angiogenesis [55]. Tenascin-C was also associated with lymphangiogenesis [56], particularly in the context of podoplanin induction [57]. The proximity of tenascin-C and tenascin-W around blood vessels prompts the question whether or not these proteins can extravasate from the tumour site and circulate in the bloodstream. Indeed, tenascin-C was found in the serum of cancer patients, but because its presence in serum was also associated with conditions other than cancer (e.g. as a consequence of infection and inflammation, see Ref. [10]), tenascin-C turned out to be a questionable serum tumour marker [58]. In contrast, tenascin-W function in adults seems to be restricted to tumourigenesis and osteogenesis (for review
Promotion of metastasis
Another more direct way for tenascin-C-triggered signals to reach the nucleus has been recently investigated in our laboratory [77] . These studies show that disruption of the physical link connecting the cell membrane to the nucleus perturbs the mechanical control of cell differentiation in the context of myogenesis. This suggests that tenascin-C-induced cytoskeletal rearrangements could also affect mechanotransduction in the frame of tumourigenesis.
It is important to note that transduction of tenascin signals to cells could also be influenced by other extracellular matrix molecules. For instance, through their binding to tenascin-C, fibronectin [78] , perlecan [79] , lectican [80] , heparin [81] , contactin [82, 83] and SMOC1 [84] have been shown to modify its effects.
Importance of the mechanical aspect
An important parameter for the progression of a tumour is the stiffness of the tissue in which it develops. Reconstruction of mammary epithelial acini in vitro has shown that the rigidity of the matrix strongly influences epithelial morphogenesis [85] . Consistently, in vivo reduction of lysyl oxidase-mediated collagen crosslinking to weaken the collagen fibres and to reduce their tensile strength decreases mammary tumour incidence [86] . Interestingly, mechanical strain not only influences features of the epithelial tumour cells themselves but may also stimulate neovascularization through activation of angiogenic genes [87] . It is therefore interesting to note that tenascin-C is induced by mechanical strain, requiring integrin-linked kinase [88] followed by RhoA/ROCK-dependent actin contractility [89] . Interestingly, fibroblasts cultured on attached, restrained collagen gels express much more tenascin-C than those cultured on floating, unrestrained collagen gels [90] . This may be an explanation why cancer-associated fibroblasts, which are exposed to high mechanical strain, overexpress tenascin-C compared to ' [92] and doxorubicin therapy [76] . Interestingly, the doxorubicin-induced G1/S arrest could be abrogated through p21 regulation, which in turn is known to be affected by the presence of tenascin-C. It was also shown that large isoforms of tenascin-C and cell surface protein annexin A2 can interact and together decrease gemcitabineinduced cytotoxicity in pancreatic cancer cells [93] . Tenascin-C might also be linked to resistance to anti-angiogenesis treatment because hypoxic tumour cells adapt by inducing new sets of genes, among which tenascin-C is found [94] .
Conclusions
We have summarized how tenascins have been shown to influence the successive steps of tumourigenesis (summarized in Fig. 2 
). Based on our knowledge of the properties of tenascin-C, two types of anti-cancer therapies have been established. The first type aims at the neutralization of its pro-tumourigenic
effects by down-regulating its expression using anti-sense oligonucleotides or aptamers (for review, see Refs. [95, 96] , respectively). The second type takes advantage of the specific overexpression of tenascin-C isoforms at tumour sites to selectively target tumour cells, using anti-tenascin-C antibody fragments coupled to a variety of anti-cancer molecules (for review, see Ref. [97] ). Further studies will be necessary to extend our knowledge to tenascin-W, but studies reported so far suggest a promising future for tenascin-W as a tumour marker and potential drug target.
